Plus: Melinda French Gates commits another $215M, and pregnancy drinking climbs to 15%.
Lilly released menopause-stage subanalyses from ATTAIN-1 and ATTAIN-2 showing its newly approved oral GLP-1 Foundayo produced up to 14.4% weight loss in perimenopausal women, the first stage-specific data for a GLP-1 pill that interacts with oral contraceptives and prices from $149 a month cash-pay. The release lands the same week Melinda French Gates committed another $215 million to women's health through Pivotal, with $10 million earmarked for menopause education. New CDC data also show drinking during pregnancy rose to 15% between 2021 and 2024. Five takes inside, plus a quick-hits roundup.
VIA FutureFemHealth
Melinda French Gates committed an additional $215 million through Pivotal for women's health, bringing her total investments in the sector to over $600 million in the past two years. Gates will expand her focus to midlife and menopause, including a $10 million grant to The Menopause Society for education and clinician training. This signals growing investor interest in a broader range of women's health issues, particularly midlife and menopause solutions.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
Over 1,500 female participants in ATTAIN-1 and ATTAIN-2 clinical trials on Foundayo, an oral GLP-1 (orforglipron), demonstrated significant weight loss across menopause stages. In ATTAIN-1, premenopausal women without diabetes lost up to 12.8%, perimenopausal women lost up to 14.4%, and post-menopausal women lost up to 14.1% of their body weight after 72 weeks on the highest dose. Foundayo's FDA approval and its potential interaction with oral birth control could impact women's health clinicians and femtech operators.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
An analysis of participants aged 12 to 35 who lost at least 10% of their body weight shows injectable semaglutide may improve fertility outcomes in women with PMOS. The ongoing RESTORE clinical trial is examining whether semaglutide can restore ovulation and improve reproductive health in adolescents and adults with PMOS. The findings suggest injectable semaglutide may become a treatment option for women with PMOS seeking improvements in both metabolic and reproductive health. Femtech operators should monitor future studies to assess semaglutide's potential as a PMOS treatment.
Read the full story →
— The Luteal Editorial Team
VIA PR Newswire – Health
Compugen Ltd. will present a trial-in-progress poster for its Phase 1 MAIA-Ovarian trial at the ESMO Gynaecological Cancers Congress 2026. The clinical-stage cancer immunotherapy company focuses on predictive computational drug target discovery. This ongoing research indicates continued development in oncology treatments relevant to femtech operators.
Read the full story →
— The Luteal Editorial Team
VIA STAT News
About 15% of adult pregnant women reported current drinking between 2021 and 2024, up from 13.5% between 2018 and 2020. This indicates an increase in drinking during pregnancy. Maternal health providers and platforms should note this trend.
Read the full story →
— The Luteal Editorial Team